Accelerating a First-in-Human Study into Rare Disease Clinical Development 

Placebo Controlled Single Blind Single Centre Phase I and Normal, Healthy Volunteers and Open Label Multicentre Study in Patients with Primary Hyperoxaluria to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of IMP Solution for Injection